By Kim Richters 

Roche Holding AG said Friday that it has received an emergency-use authorization from the U.S. Food and Drug Administration for its Actemra/RoActemra drug to treat certain patients with Covid-19.

The Swiss pharmaceutical major said the authorization allows for emergency use of Actemra/RoActemra for the treatment of Covid-19 in hospitalized adults and children who are at least 2 years old.

The FDA's decision is based on the results of four randomized, controlled studies with more than 5,500 hospitalized patients.

"The results of these studies suggest that Actemra/RoActemra may improve outcomes in patients receiving corticosteroids and requiring supplemental oxygen or breathing support," Roche said.

Roche said this authorization is temporary and doesn't replace a formal review and approval process.


Write to Kim Richters at


(END) Dow Jones Newswires

June 25, 2021 02:42 ET (06:42 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Roche (QX) Charts.
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Roche (QX) Charts.